Protocol Design Featured Articles

  1. The Promise Of MRD-Guided CAR-T Treatment 9/3/2026

    Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.

  2. Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials 9/2/2026

    Aprea’s Gene Kennedy explains how smart dose escalation, next-gen sequencing, and combination planning are helping the company advance its oncology trial for multiple solid tumor types.

  3. Turning A Historically Limited Modality Into A Respiratory Drug Opportunity 8/26/2026

    How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.

  4. Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy 8/25/2026

    Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

  5. 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations 8/24/2026

    Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

  6. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

    BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

  7. 'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint 8/21/2026

    Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.

  8. Building The Execution Architecture For Real-World Data To Have Real-World Impact 8/20/2026

    RWE's next challenge is execution. Learn how life sciences orgns can turn evidence into sustained business and clinical impact.

  9. Stock Options: Choosing The Right Viral Inoculum For An Early-Phase Norovirus Trial 8/20/2026

    Viral stock can make or break a norovirus challenge study. Cocrystal Pharma's Sam Lee explains why inoculum quality, infectivity, and availability matter.

  10. Rare Disease Study Gets A Boost From Crowdsourced Patient Reported Data 8/18/2026

    Jen A. Levitt, MD, explains how crowdsourced patient-reported data and AI tools can compress rare disease research timelines and surface new signals.